---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-088234"
form_type: "8-K"
ticker: "AMRN"
cik: "0000897448"
company_name: "AMARIN CORP PLCUK"
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:43:29.366243+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Amarin Q2 revenue down 16% to $67.5M; PBM drops VASCEPA coverage; new CEO

## Summary
- Total net revenue $67.5M (-16% YoY); net product revenue $47.5M (-27%) pressured by US generic competition.
- GAAP net income $1.5M (EPS $0.00) vs net loss $17.6M in Q2 2023; non-GAAP adj. net income $5.9M.
- Cash $306.7M; $50M share repurchase program approved but not commenced.
- Large PBM removed VASCEPA from exclusive coverage for Commercial national formularies effective July 1, 2024.
- CEO Aaron Berg appointed; China CVRR milestone $15M; new EU patent extending VAZKEPA exclusivity to 2039.

## SEC filing metadata
- accession: 0000950170-24-088234
- form_type: 8-K
- ticker: AMRN
- cik: 0000897448
- company_name: AMARIN CORP PLCUK
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/897448/000095017024088234/0000950170-24-088234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/897448/000095017024088234/amrn-20240731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-088234
- JSON: https://secwatch.observer/filing/0000950170-24-088234.json
- Plain text: https://secwatch.observer/filing/0000950170-24-088234.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.